Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with offices in Nashville, today ...

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

Cedars-Sinai physician-scientists joined peers from around the world at the Alzheimer's Association International Conference ...

With Human Research Ethics Committee (HREC) approval already secured, Oragenics is working closely with Southern Star to complete site selection, finalize investigator agreements, and prepare for ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Phase 1 study results published in Nature Medicine looks at a vaccine for patients with pancreatic and colorectal cancer. Dr Magnus Dillon, Clinician Scientist at The Institute of Cancer Research, ...

Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.